Results from a Global Phase 3 Trial (IB1001-303) Evaluating N-acetyl-L-leucine in Ataxiatelangiectasia (P11-7.004)

Puntos clave

• The aim is to assess the efficacy and safety of N-acetyl-L-leucine in individuals with Ataxia-Telangiectasia.
• Global phase 3 randomized trial (IB1001-303) with a placebo-controlled, double-blind crossover design.
• Participants were assessed for efficacy and safety.
• The trial involved treatment with N-acetyl-L-leucine.
• N-acetyl-L-leucine showed a significant improvement in the primary efficacy endpoint compared to placebo (p<0.01).
• Safety profile of N-acetyl-L-leucine was consistent with previous studies, with no new safety concerns identified.